Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA7 | P43166 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 2/20 | 0.32 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.32 |
| ▸ | CASR | P41180 | 1/20 | 0.32 |
| ▸ | ING2 | Q9H160 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6296713 | 0.97 | LCK (0.47) | LCKFYNCA12CA1CA2 | |
| SCHEMBL6856344 | 0.86 | CA12 (0.55) | LCKFYNCA12CA1CA2 | |
| SCHEMBL27647413 | 0.83 | CA12 (0.55) | LCKFYNCA12CA1CA2 | |
| SCHEMBL27647424 | 0.83 | CA12 (0.55) | LCKFYNCA12CA1CA2 | |
| SCHEMBL27668044 | 0.83 | CA12 (0.55) | LCKFYNCA12CA1CA2 | |
| SCHEMBL27647403 | 0.83 | CA12 (0.55) | LCKFYNCA12CA1CA2 | |
| SCHEMBL6291905 | 0.83 | CA12 (0.55) | LCKFYNCA12CA1CA2 | |
| SCHEMBL27647445 | 0.83 | CA12 (0.55) | LCKFYNCA12CA1CA2 | |
| SCHEMBL6856358 | 0.82 | CA12 (0.39) | LCKFYNCA12CA1CA2 | |
| SCHEMBL6296712 | 0.82 | CA12 (0.39) | LCKFYNCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6830859-B2 | Electrostatic latent images; containing barium salt of sulfoisophthalic acid | RICOH COMPANY, LTD. (JP) | 2004-12-14 | — | — | US | disclosed |
| US-20030077534-A1 | Charge control agent and toner using same | RICOH COMPANY, LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030077534-A1 | Charge control agent and toner using same | BET1, SMARCA5, SMARCA1 | LCK 3088/4885FYN 3103/4885CA12 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.